Miriam Kolko
Miriam Kolko is an expert in Ophthalmology at Rigshospitalet (Denmark). As of October 2026, ScienceLeadR ranks Miriam Kolko in the top 1% of experts worldwide for Glaucoma and Ocular Hypertension. Miriam Kolko has authored 229 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 4 of them ongoing. SLR score: 845 (community average: 125). How the SLR is computed.
LeadR Profile
Ophthalmology
Subspecialties: Biochemistry - Otolaryngology - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1999 - 2026
Number : 229
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Low-level light therapy for dry eye disease and meibomian gland dysfunction: A systematic review and meta-analysis. PMID 42860563 — tears, signs and symptoms, phototherapy, eye diseases, therapeutics, meibomian glands, dry eye syndromes, meibomian gland dysfunction, low-level light therapy | Acta Ophthalmol | 2026 | 0 |
| Isotretinoin and Dry Eye Disease: A Systematic Review. PMID 42554012 — isotretinoin, ophthalmology, signs and symptoms, sebaceous glands, eye diseases, meibomian glands, dry eye syndromes | Curr Eye Res | 2026 | 0 |
| Galectin-3 is elevated in Müller glia in human glaucomatous eyes and ocular hypertensive rat eyes and associated with phagocytosing states. PMID 42552556 — eye, cells, genes, galectins, retina, galectin 3, retinal ganglion cells, neuroglia, glaucoma, ganglion cysts, nervous system diseases, retinaldehyde | Acta Neuropathol Commun | 2026 | 0 |
| Rethinking Dry Eye and Ocular Surface Disesase in Glaucoma: Pathophysiology, Diagnosis, and Management. PMID 42339994 — eye, quality of life, glaucoma, prevalence, diagnosis, therapeutics | J Glaucoma | 2026 | 0 |
| Rethinking Dry Eye and Ocular Surface Disease in Glaucoma: Pathophysiology, Diagnosis, and Management. PMID 42340748 — eye, quality of life, glaucoma, prevalence, diagnosis, therapeutics, dry eye syndromes | J Glaucoma | 2026 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Additive Benefits of Semaglutide for open AngLe glaucoma an Opportunity for Neuroprotection (ABSALON) 2024-518510-87-00 — glaucoma, open-angle, neuroprotection, glaucoma, semaglutide | Phase 4 | Recruiting | 2025 |
| A Study Investigating Oral Semaglutide in People with Open Angle Glaucoma NCT06792422 — glucagon-like peptide 1, glaucoma, open-angle, neuroprotection, tablets, maintenance, glaucoma, semaglutide | Phase 4 | Recruiting | 2025 |
| Danish Angle Closure Prevention Trial NCT06077253 — glaucoma | N/A | Recruiting | 2023 |
| Effect of Benzalkonium Chloride Preserved and Preservative free Latanoprost Eye Drops on Conjunctival Goblet Cells NCT04957329 — eye, cells, hypertension, ophthalmology, glaucoma, latanoprost, ocular hypertension, goblet cells | Phase 4 | Recruiting | 2021 |
LeadR Networks
Main global connection map